HLA-B13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients

HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies hav...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 661135
Main Authors Satapornpong, Patompong, Pratoomwun, Jirawat, Rerknimitr, Pawinee, Klaewsongkram, Jettanong, Nakkam, Nontaya, Rungrotmongkol, Thanyada, Konyoung, Parinya, Saksit, Niwat, Mahakkanukrauh, Ajanee, Amornpinyo, Warayuwadee, Khunarkornsiri, Usanee, Tempark, Therdpong, Wantavornprasert, Kittipong, Jinda, Pimonpan, Koomdee, Napatrupron, Jantararoungtong, Thawinee, Rerkpattanapipat, Ticha, Wang, Chuang-Wei, Naisbitt, Dean, Tassaneeyakul, Wichittra, Ariyachaipanich, Manasalak, Roonghiranwat, Thapana, Pirmohamed, Munir, Chung, Wen-Hung, Sukasem, Chonlaphat
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.05.2021
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2021.661135

Cover

Loading…
Abstract HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9 , CYP2C19 , and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10 −7 ), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10 −3 ), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10 −5 ) as compared to dapsone-tolerant controls. Also , HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10 −7 ) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10 −3 ). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 ( CYP2C9 , CYP2C19 , and CYP3A4 ) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
AbstractList HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10-7), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10-3), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10-5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10-7) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10-3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10-7), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10-3), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10-5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10-7) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10-3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9 , CYP2C19 , and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10 −7 ), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10 −3 ), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10 −5 ) as compared to dapsone-tolerant controls. Also , HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10 −7 ) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10 −3 ). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 ( CYP2C9 , CYP2C19 , and CYP3A4 ) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). , , and genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with and alleles by the molecular docking approach. Among all the alleles, only allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67-198.21, p = 5.3447 × 10 ), SJS-TEN (OR = 36.00, 95% CI = 3.19-405.89, p = 2.1657 × 10 ), and DRESS (OR = 40.50, 95% CI = 6.38-257.03, p = 1.0784 × 10 ) as compared to dapsone-tolerant controls. Also allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67-149.52, p = 2.8068 × 10 ) and Taiwanese (OR = 31.50, 95% CI = 4.80-206.56, p = 2.5519 × 10 ). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 ( , , and ) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10−7), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10−3), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10−5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10−7) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10−3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population.
Author Satapornpong, Patompong
Konyoung, Parinya
Jantararoungtong, Thawinee
Tassaneeyakul, Wichittra
Khunarkornsiri, Usanee
Chung, Wen-Hung
Jinda, Pimonpan
Rerknimitr, Pawinee
Naisbitt, Dean
Klaewsongkram, Jettanong
Koomdee, Napatrupron
Rungrotmongkol, Thanyada
Rerkpattanapipat, Ticha
Roonghiranwat, Thapana
Pirmohamed, Munir
Ariyachaipanich, Manasalak
Sukasem, Chonlaphat
Pratoomwun, Jirawat
Mahakkanukrauh, Ajanee
Wantavornprasert, Kittipong
Wang, Chuang-Wei
Amornpinyo, Warayuwadee
Saksit, Niwat
Nakkam, Nontaya
Tempark, Therdpong
AuthorAffiliation 6 Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand
2 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital , Bangkok , Thailand
14 Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
21 Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool , Liverpool , United Kingdom
3 Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University , Pathum Thani , Thailand
4 Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University , Samut Prakan , Thailand
25 Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan
15 Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital , Khon Kaen , Thailand
1 Division of Pharmacogenomics and Personalized Medicine, Department of Pa
AuthorAffiliation_xml – name: 18 Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital (CGMH) , Taipei , Taiwan
– name: 3 Division of General Pharmacy Practice, Department of Pharmaceutical Care, College of Pharmacy, Rangsit University , Pathum Thani , Thailand
– name: 7 Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand
– name: 12 Pharmacy Unit, Udon Thani Hospital , Udon Thani , Thailand
– name: 1 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand
– name: 9 Department of Pharmacology, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
– name: 10 Biocatalyst and Environmental Biotechnology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University , Bangkok , Thailand
– name: 15 Division of Dermatology, Department of Internal Medicine, Khon Kaen Hospital , Khon Kaen , Thailand
– name: 14 Department of Medicine, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand
– name: 8 King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok , Thailand
– name: 11 Program in Bioinformatics and Computational Biology, Graduated School, Chulalongkorn University , Bangkok , Thailand
– name: 22 Skin Center, Ruampaet Dr.ANAN Hospital , Surin , Thailand
– name: 23 Department of Pediatrics, Prapokklao Hospital , Chantaburi , Thailand
– name: 19 Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan
– name: 2 Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital , Bangkok , Thailand
– name: 26 The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group , Bangkok , Thailand
– name: 4 Department of Clinical Chemistry, Faculty of Medical Technology, Huachiew Chalermprakiet University , Samut Prakan , Thailand
– name: 20 Department of Dermatology, Xiamen Chang Gung Hospital , Xiamen , China
– name: 25 Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital , Linkou , Taiwan
– name: 24 Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital , Keelung , Taiwan
– name: 17 Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , Bangkok , Thailand
– name: 6 Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand
– name: 5 The Skin and Allergy Research Unit, Chulalongkorn University , Bangkok , Thailand
– name: 16 Division of Dermatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand
– name: 13 Unit of Excellence on Pharmacogenomic Pharmacokinetic and Pharmacotherapeutic Researches (UPPER), School of Pharmaceutical Sciences, University of Phayao , Phayao , Thailand
– name: 21 Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool , Liverpool , United Kingdom
Author_xml – sequence: 1
  givenname: Patompong
  surname: Satapornpong
  fullname: Satapornpong, Patompong
– sequence: 2
  givenname: Jirawat
  surname: Pratoomwun
  fullname: Pratoomwun, Jirawat
– sequence: 3
  givenname: Pawinee
  surname: Rerknimitr
  fullname: Rerknimitr, Pawinee
– sequence: 4
  givenname: Jettanong
  surname: Klaewsongkram
  fullname: Klaewsongkram, Jettanong
– sequence: 5
  givenname: Nontaya
  surname: Nakkam
  fullname: Nakkam, Nontaya
– sequence: 6
  givenname: Thanyada
  surname: Rungrotmongkol
  fullname: Rungrotmongkol, Thanyada
– sequence: 7
  givenname: Parinya
  surname: Konyoung
  fullname: Konyoung, Parinya
– sequence: 8
  givenname: Niwat
  surname: Saksit
  fullname: Saksit, Niwat
– sequence: 9
  givenname: Ajanee
  surname: Mahakkanukrauh
  fullname: Mahakkanukrauh, Ajanee
– sequence: 10
  givenname: Warayuwadee
  surname: Amornpinyo
  fullname: Amornpinyo, Warayuwadee
– sequence: 11
  givenname: Usanee
  surname: Khunarkornsiri
  fullname: Khunarkornsiri, Usanee
– sequence: 12
  givenname: Therdpong
  surname: Tempark
  fullname: Tempark, Therdpong
– sequence: 13
  givenname: Kittipong
  surname: Wantavornprasert
  fullname: Wantavornprasert, Kittipong
– sequence: 14
  givenname: Pimonpan
  surname: Jinda
  fullname: Jinda, Pimonpan
– sequence: 15
  givenname: Napatrupron
  surname: Koomdee
  fullname: Koomdee, Napatrupron
– sequence: 16
  givenname: Thawinee
  surname: Jantararoungtong
  fullname: Jantararoungtong, Thawinee
– sequence: 17
  givenname: Ticha
  surname: Rerkpattanapipat
  fullname: Rerkpattanapipat, Ticha
– sequence: 18
  givenname: Chuang-Wei
  surname: Wang
  fullname: Wang, Chuang-Wei
– sequence: 19
  givenname: Dean
  surname: Naisbitt
  fullname: Naisbitt, Dean
– sequence: 20
  givenname: Wichittra
  surname: Tassaneeyakul
  fullname: Tassaneeyakul, Wichittra
– sequence: 21
  givenname: Manasalak
  surname: Ariyachaipanich
  fullname: Ariyachaipanich, Manasalak
– sequence: 22
  givenname: Thapana
  surname: Roonghiranwat
  fullname: Roonghiranwat, Thapana
– sequence: 23
  givenname: Munir
  surname: Pirmohamed
  fullname: Pirmohamed, Munir
– sequence: 24
  givenname: Wen-Hung
  surname: Chung
  fullname: Chung, Wen-Hung
– sequence: 25
  givenname: Chonlaphat
  surname: Sukasem
  fullname: Sukasem, Chonlaphat
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34017337$$D View this record in MEDLINE/PubMed
BookMark eNp9Uktv1DAQtlARLaU_gAvykUsWO3acmAPSsjy60iIqKGdrYk9al2y82MlK_Hu8TalaDvhia_w9PJ7vOTkawoCEvORsIUSj33R-u50WJSv5QinORfWEnHClZCHKUh49OB-Ts5RuWF5SCyGqZ-RYSMZrIeoT4s83y-I9F_Qt43SdKNCLiM7b0e-RfoH4EyMNHf0Au5Tti_XgJouOfsc9RqSraYQBw5To0uVCQvoNIXPDkKgf6OU1eHoBo8dhTC_I0w76hGd3-yn58enj5eq82Hz9vF4tN4WtBB8LpRTo1goFrpSWi1KCqjsU2urGNW1T6aopK1CiZqqVSgJTucxl1QCTjQBxStazrgtwY3bRbyH-NgG8uS2EeGUgjt72aFwHVdeKttXWSmyllpWteeM0c62zFWatd7PWbmq36GzuI0L_SPTxzeCvzVXYm4YLpmqeBV7fCcTwa8I0mq1PFvt-_jZT5p5L3tT6AH310Ove5O-sMoDPABtDShG7ewhn5hAJcxsJc4iEmSOROfU_HOtHOAwoP9f3_2H-AU5Eu0o
CitedBy_id crossref_primary_10_1111_bcp_15054
crossref_primary_10_1016_j_heliyon_2024_e26713
crossref_primary_10_3389_fphar_2023_1183491
crossref_primary_10_1186_s12929_022_00845_8
crossref_primary_10_3389_fitd_2022_893653
crossref_primary_10_1007_s00251_022_01264_7
crossref_primary_10_1016_j_hlife_2023_10_003
crossref_primary_10_1080_03602532_2025_2453521
crossref_primary_10_1080_17425255_2021_1946514
crossref_primary_10_3389_fmed_2023_1187937
crossref_primary_10_1016_j_jaip_2022_04_027
crossref_primary_10_4049_jimmunol_2200531
crossref_primary_10_1080_17425255_2025_2455388
crossref_primary_10_1097_JD9_0000000000000178
crossref_primary_10_1007_s13671_021_00348_z
crossref_primary_10_3389_fphar_2022_886377
crossref_primary_10_3390_ph14111077
crossref_primary_10_1097_FPC_0000000000000517
crossref_primary_10_1016_j_isci_2023_107391
crossref_primary_10_1093_pnasnexus_pgae140
crossref_primary_10_7759_cureus_62269
crossref_primary_10_3389_fphar_2022_867490
crossref_primary_10_3389_fphar_2022_891838
crossref_primary_10_3390_medicina59010056
crossref_primary_10_1007_s11882_023_01109_7
crossref_primary_10_1097_ACI_0000000000000914
crossref_primary_10_1016_j_heliyon_2024_e34977
crossref_primary_10_1016_j_jaip_2022_02_004
crossref_primary_10_1080_17512433_2022_2100345
crossref_primary_10_3390_ijms26020680
crossref_primary_10_1080_13696998_2023_2270868
crossref_primary_10_1016_j_jaci_2022_12_005
crossref_primary_10_3389_falgy_2024_1481281
crossref_primary_10_3389_fphar_2022_954596
crossref_primary_10_3390_biomedicines11010177
Cites_doi 10.1016/S0190-9622(96)90667-2
10.1080/14740338.2020.1796965
10.1016/j.alit.2016.04.001
10.1186/s13601-015-0073-8
10.1038/jid.2013.192
10.1097/FPC.0000000000000306
10.1258/004947507781524700
10.1056/NEJMoa1213096
10.1590/S0104-42302012000300003
10.1016/j.jdermsci.2017.08.007
10.1038/s41598-019-46668-w
10.3349/ymj.2016.57.1.118
10.1001/archderm.129.1.92
10.2340/00015555-1268
10.1093/hmg/ddq537
10.1056/NEJMoa1013297
10.1111/j.1365-4632.2010.04593.x
10.1007/s00403-013-1409-7
10.4103/0378-6323.57718
10.1592/phco.24.9.856.36106
10.1111/j.1346-8138.2010.01196.x
10.1001/jamadermatol.2019.2609
10.3390/cancers11040437
10.1080/17425255.2018.1441285
10.4103/0022-3859.81865
10.5415/apallergy.2015.5.2.59
10.1038/srep04862
10.1001/jamadermatol.2017.6484
10.1146/annurev-pharmtox-010611-134701
10.1016/j.therap.2016.12.009
10.1097/00008571-200011000-00005
10.1097/FPC.0000000000000153
10.3389/fphar.2020.00078
10.2217/pgs.12.108
10.1038/428486a
10.12788/j.sder.0059
10.1056/NEJM199411103311906
10.1111/all.13769
10.1001/jama.2014.14148
10.1016/j.jaci.2011.12.990
10.1111/j.1533-2500.2011.00479.x
10.5935/0103-5053.20140168
10.1111/jcpt.12048
10.1111/j.1365-2133.2012.11074.x
10.1590/S0365-05962012000300013
10.1371/journal.pntd.0008746
10.5935/0305-7518.20010009
10.1097/FPC.0000000000000211
10.1001/jama.286.18.2270
10.1038/clpt.2013.5
10.1159/000448217
10.1067/mjd.2001.114733
10.1016/s0198-8859(01)00298-1
10.4269/ajtmh.16-0628
10.1503/cmaj.111152
10.1111/j.1365-2133.2006.07284.x
ContentType Journal Article
Copyright Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem.
Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem
Copyright_xml – notice: Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem.
– notice: Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2021.661135
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_dfa5fb3bb9cc4eb4945c718d90dbdc5e
PMC8130671
34017337
10_3389_fimmu_2021_661135
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: MR/L006758/1
– fundername: Medical Research Council
  grantid: G0700654
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c531t-666a9bc36ad24c1324a67fe39c98d8b8595825a63706b464a06d8b1458a0483a3
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:31:26 EDT 2025
Thu Aug 21 14:03:24 EDT 2025
Fri Jul 11 13:13:52 EDT 2025
Sat May 31 02:07:53 EDT 2025
Thu Apr 24 22:58:44 EDT 2025
Tue Jul 01 01:32:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords HLA-B13:01
HLA class I and II alleles
Thais and Taiwaneses
cytochrome P450
dapsone-induced severe cutaneous adverse reactions
Language English
License Copyright © 2021 Satapornpong, Pratoomwun, Rerknimitr, Klaewsongkram, Nakkam, Rungrotmongkol, Konyoung, Saksit, Mahakkanukrauh, Amornpinyo, Khunarkornsiri, Tempark, Wantavornprasert, Jinda, Koomdee, Jantararoungtong, Rerkpattanapipat, Wang, Naisbitt, Tassaneeyakul, Ariyachaipanich, Roonghiranwat, Pirmohamed, Chung and Sukasem.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c531t-666a9bc36ad24c1324a67fe39c98d8b8595825a63706b464a06d8b1458a0483a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Mayumi Ueta, Kyoto Prefectural University of Medicine, Japan; Teresa Bellon, University Hospital La Paz Research Institute (IdiPAZ), Spain
Edited by: Luis Eduardo Coelho Andrade, Federal University of São Paulo, Brazil
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
OpenAccessLink https://doaj.org/article/dfa5fb3bb9cc4eb4945c718d90dbdc5e
PMID 34017337
PQID 2531218791
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_dfa5fb3bb9cc4eb4945c718d90dbdc5e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8130671
proquest_miscellaneous_2531218791
pubmed_primary_34017337
crossref_primary_10_3389_fimmu_2021_661135
crossref_citationtrail_10_3389_fimmu_2021_661135
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-05-04
PublicationDateYYYYMMDD 2021-05-04
PublicationDate_xml – month: 05
  year: 2021
  text: 2021-05-04
  day: 04
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Rao (B4) 2001; 72
Zhao (B56) 2019; 74
Satapornpong (B41) 2020; 11
Park (B40) 2016; 57
Bastuji-Garin (B30) 1993; 129
Krismawati (B36) 2020; 14
Harp (B8) 2014; 33
Park (B37) 2020; 19
Wozel (B52) 2014; 306
Dao (B58) 2015; 5
Then (B18) 2011; 29
Peyriere (B14) 2006; 155
Kulkantrakorn (B20) 2012; 12
Tempark (B27) 2017; 27
Mehta (B19) 2009; 75
Wang (B25) 2013; 133
Negrini (B49) 2017; 72
Oliveira (B29) 2014; 25
Kongpan (B48) 2015; 25
Tangamornsuksan (B50) 2018; 154
Pandey (B5) 2007; 37
Lorenz (B55) 2012; 92
Barvaliya (B46) 2011; 57
Sullivan (B15) 2018; 14
Aihara (B12) 2011; 38
Pavlos (B35) 2012; 13
Mahalapbutr (B33) 2019; 11
Cao (B43) 2001; 62
Ho (B53) 2011; 183
Sousa-Pinto (B9) 2016; 170
Ueta (B31) 2014; 4
Wei (B57) 2012; 129
Zhu (B1) 2001; 45
Mahalapbutr (B32) 2019; 9
Hiransuthikul (B7) 2016; 65
McCormack (B22) 2011; 364
Criado (B13) 2012; 87
Amstutz (B42) 2013; 94
Zhang (B26) 2013; 369
Roujeau (B47) 1994; 331
Bharadwaj (B34) 2012; 52
Schrijvers (B39) 2015; 5
Ozeki (B21) 2011; 20
Prussick (B3) 1996; 35
Marotti (B10) 2012; 58
Pirmohamed (B54) 2000; 10
Shen (B6) 2011; 50
Lee (B11) 2012; 167
Tingle (B28) 1997; 283
Watanabe (B51) 2017; 88
Brackett (B45) 2004; 24
Ghimire (B44) 2013; 38
Liu (B38) 2019; 155
Phillips (B16) 2001; 286
Chung (B17) 2004; 428
Wang (B2) 2017; 96
Chung (B23) 2014; 312
Tassaneeyakul (B24) 2016; 26
References_xml – volume: 35
  year: 1996
  ident: B3
  article-title: Dapsone Hypersensitivity Syndrome
  publication-title: J Am Acad Dermatol
  doi: 10.1016/S0190-9622(96)90667-2
– volume: 19
  year: 2020
  ident: B37
  article-title: The HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome in Korean and Asian Populations: Genotype- and Meta-Analyses
  publication-title: Expert Opin Drug Saf
  doi: 10.1080/14740338.2020.1796965
– volume: 65
  year: 2016
  ident: B7
  article-title: Drug-Induced Hypersensitivity Syndrome/Drug Reaction With Eosinophilia and Systemic Symptoms (Dihs/Dress): 11 Years Retrospective Study in Thailand
  publication-title: Allergol Int
  doi: 10.1016/j.alit.2016.04.001
– volume: 5
  start-page: 5
  year: 2015
  ident: B39
  article-title: Pathogenesis and Diagnosis of Delayed-Type Drug Hypersensitivity Reactions, From Bedside to Bench and Back
  publication-title: Clin Transl Allergy
  doi: 10.1186/s13601-015-0073-8
– volume: 133
  year: 2013
  ident: B25
  article-title: Association Between Hla-B*1301 and Dapsone-Induced Hypersensitivity Reactions Among Leprosy Patients in China
  publication-title: J Invest Dermatol
  doi: 10.1038/jid.2013.192
– volume: 27
  year: 2017
  ident: B27
  article-title: Dapsone-Induced Severe Cutaneous Adverse Drug Reactions are Strongly Linked With Hla-B*13: 01 Allele in the Thai Population
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000306
– volume: 37
  year: 2007
  ident: B5
  article-title: Mortality Due to Dapsone Hypersensitivity Syndrome Complicating Multi-Drug Therapy for Leprosy in Nepal
  publication-title: Trop Doct
  doi: 10.1258/004947507781524700
– volume: 369
  year: 2013
  ident: B26
  article-title: HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1213096
– volume: 58
  year: 2012
  ident: B10
  article-title: Severe Cutaneous Adverse Reactions (Scar) Syndromes
  publication-title: Rev Assoc Med Bras
  doi: 10.1590/S0104-42302012000300003
– volume: 88
  year: 2017
  ident: B51
  article-title: A Docking Model of Dapsone Bound to HLA-B*13:01 Explains the Risk of Dapsone Hypersensitivity Syndrome
  publication-title: J Dermatol Sci
  doi: 10.1016/j.jdermsci.2017.08.007
– volume: 9
  start-page: 1
  year: 2019
  ident: B32
  article-title: Atomistic Mechanisms Underlying the Activation of the G Protein-Coupled Sweet Receptor Heterodimer by Sugar Alcohol Recognition
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-46668-w
– volume: 57
  year: 2016
  ident: B40
  article-title: Hla Allele Frequencies in 5802 Koreans: Varied Allele Types Associated With SJS/TEN According to Culprit Drugs
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2016.57.1.118
– volume: 129
  year: 1993
  ident: B30
  article-title: Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme
  publication-title: Arch Dermatol
  doi: 10.1001/archderm.129.1.92
– volume: 92
  year: 2012
  ident: B55
  article-title: Hypersensitivity Reactions to Dapsone: A Systematic Review
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-1268
– volume: 29
  year: 2011
  ident: B18
  article-title: Frequency of the HLA-B*1502 Allele Contributing to Carbamazepine-Induced Hypersensitivity Reactions in a Cohort of Malaysian Epilepsy Patients
  publication-title: Asian Pac J Allergy Immunol
– volume: 20
  year: 2011
  ident: B21
  article-title: Genome-Wide Association Study Identifies Hla-a*3101 Allele as a Genetic Risk Factor for Carbamazepine-Induced Cutaneous Adverse Drug Reactions in Japanese Population
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddq537
– volume: 364
  year: 2011
  ident: B22
  article-title: Hla-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1013297
– volume: 50
  start-page: 57
  year: 2011
  ident: B6
  article-title: Causes of Death Among Active Leprosy Patients in China
  publication-title: Int J Dermatol
  doi: 10.1111/j.1365-4632.2010.04593.x
– volume: 306
  year: 2014
  ident: B52
  article-title: Dapsone in Dermatology and Beyond
  publication-title: Arch Dermatol Res
  doi: 10.1007/s00403-013-1409-7
– volume: 75
  year: 2009
  ident: B19
  article-title: Association of HLA-B*1502 Allele and Carbamazepine-Induced Stevens–Johnson Syndrome Among Indians
  publication-title: Indian J Dermatol Venereol Leprol
  doi: 10.4103/0378-6323.57718
– volume: 283
  year: 1997
  ident: B28
  article-title: Comparison of the Metabolism and Toxicity of Dapsone in Rat, Mouse and Man
  publication-title: J Pharmacol Exp Ther
– volume: 24
  year: 2004
  ident: B45
  article-title: Likelihood and Mechanisms of Cross-Allergenicity Between Sulfonamide Antibiotics and Other Drugs Containing a Sulfonamide Functional Group
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.24.9.856.36106
– volume: 38
  year: 2011
  ident: B12
  article-title: Pharmacogenetics of Cutaneous Adverse Drug Reactions
  publication-title: J Dermatol
  doi: 10.1111/j.1346-8138.2010.01196.x
– volume: 155
  year: 2019
  ident: B38
  article-title: Evaluation of Prospective Hla-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2019.2609
– volume: 11
  start-page: 1
  year: 2019
  ident: B33
  article-title: Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11040437
– volume: 14
  year: 2018
  ident: B15
  article-title: Implications of HLA-allele Associations for the Study of Type Iv Drug Hypersensitivity Reactions
  publication-title: Expert Opin Drug Metab Toxicol
  doi: 10.1080/17425255.2018.1441285
– volume: 57
  year: 2011
  ident: B46
  article-title: Drug-Induced Stevens-Johnson Syndrome (Sjs), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap: A Multicentric Retrospective Study
  publication-title: J Postgrad Med
  doi: 10.4103/0022-3859.81865
– volume: 5
  start-page: 59
  year: 2015
  ident: B58
  article-title: Recent Advances of Pharmacogenomics in Severe Cutaneous Adverse Reactions: Immune and Nonimmune Mechanisms
  publication-title: Asia Pac Allergy
  doi: 10.5415/apallergy.2015.5.2.59
– volume: 4
  start-page: 1
  year: 2014
  ident: B31
  article-title: Independent Strong Association of HLA-A*02:06 and HLA-B*44:03 With Cold Medicine-Related Stevens-Johnson Syndrome With Severe Mucosal Involvement
  publication-title: Sci Rep
  doi: 10.1038/srep04862
– volume: 154
  year: 2018
  ident: B50
  article-title: Association Between Hla-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2017.6484
– volume: 52
  year: 2012
  ident: B34
  article-title: Drug Hypersensitivity and Human Leukocyte Antigens of the Major Histocompatibility Complex
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev-pharmtox-010611-134701
– volume: 72
  year: 2017
  ident: B49
  article-title: Pharmacogenetics of Hypersensitivity Drug Reactions
  publication-title: Therapie
  doi: 10.1016/j.therap.2016.12.009
– volume: 10
  year: 2000
  ident: B54
  article-title: Association Analysis of Drug Metabolizing Enzyme Gene Polymorphisms in HIV-positive Patients With Co-Trimoxazole Hypersensitivity
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200011000-00005
– volume: 25
  year: 2015
  ident: B48
  article-title: Candidate HLA Genes for Prediction of Co-Trimoxazole-Induced Severe Cutaneous Reactions
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000153
– volume: 11
  start-page: 1
  year: 2020
  ident: B41
  article-title: Genetic Diversity of HLA Class I and Class Ii Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.00078
– volume: 13
  year: 2012
  ident: B35
  article-title: HLA and Pharmacogenetics of Drug Hypersensitivity
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.12.108
– volume: 428
  start-page: 486
  year: 2004
  ident: B17
  article-title: Medical Genetics: A Marker for Stevens-Johnson Syndrome
  publication-title: Nature
  doi: 10.1038/428486a
– volume: 33
  start-page: 17
  year: 2014
  ident: B8
  article-title: Severe Cutaneous Adverse Reactions Impact of Immunology Genetics and Pharmacology
  publication-title: Semin Cutan Med Surg
  doi: 10.12788/j.sder.0059
– volume: 331
  year: 1994
  ident: B47
  article-title: Severe Adverse Cutaneous Reactions to Drugs
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199411103311906
– volume: 74
  year: 2019
  ident: B56
  article-title: Dapsone- and Nitroso Dapsone-Specific Activation of T Cells From Hypersensitive Patients Expressing the Risk Allele Hla-B*13:01
  publication-title: Allergy
  doi: 10.1111/all.13769
– volume: 312
  year: 2014
  ident: B23
  article-title: Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions
  publication-title: JAMA
  doi: 10.1001/jama.2014.14148
– volume: 129
  year: 2012
  ident: B57
  article-title: Direct Interaction Between HLA-B and Carbamazepine Activates T Cells in Patients With Stevens-Johnson Syndrome
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2011.12.990
– volume: 12
  year: 2012
  ident: B20
  article-title: Hla-B*1502 Strongly Predicts Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients With Neuropathic Pain
  publication-title: Pain Pract
  doi: 10.1111/j.1533-2500.2011.00479.x
– volume: 25
  year: 2014
  ident: B29
  article-title: Clinical Applications and Methemoglobinemia Induced by Dapsone
  publication-title: J Braz Chem Soc
  doi: 10.5935/0103-5053.20140168
– volume: 38
  start-page: 196
  year: 2013
  ident: B44
  article-title: An Evidence-Based Approach for Providing Cautionary Recommendations to Sulfonamide-Allergic Patients and Determining Cross-Reactivity Among Sulfonamide-Containing Medications
  publication-title: J Clin Pharm Ther
  doi: 10.1111/jcpt.12048
– volume: 167
  year: 2012
  ident: B11
  article-title: The Role of Prior Corticosteroid Use on the Clinical Course of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Case-Control Analysis of Patients Selected From the Multinational EuroSCAR and RegiSCAR Studies
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2012.11074.x
– volume: 87
  year: 2012
  ident: B13
  article-title: Drug Reaction With Eosinophilia and Systemic Symptoms (Dress) / Drug-induced Hypersensitivity Syndrome (Dihs): A Review of Current Concepts
  publication-title: Bras Dermatol
  doi: 10.1590/S0365-05962012000300013
– volume: 14
  start-page: 1
  year: 2020
  ident: B36
  article-title: Validation Study of HLA-B*13:01 as a Biomarker of Dapsone Hypersensitivity Syndrome in Leprosy Patients in Indonesia
  publication-title: PloS Negl Trop Dis
  doi: 10.1371/journal.pntd.0008746
– volume: 72
  start-page: 57
  year: 2001
  ident: B4
  article-title: Increase in the Incidence of Dapsone Hypersensitivity Syndrome an Appraisal
  publication-title: Lepr Rev
  doi: 10.5935/0305-7518.20010009
– volume: 26
  year: 2016
  ident: B24
  article-title: Associations Between Hla Class I and Cytochrome P450 2c9 Genetic Polymorphisms and Phenytoin-Related Severe Cutaneous Adverse Reactions in a Thai Population
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000211
– volume: 286
  year: 2001
  ident: B16
  article-title: Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
  publication-title: JAMA
  doi: 10.1001/jama.286.18.2270
– volume: 94
  year: 2013
  ident: B42
  article-title: HLA-A 31:01 and HLA-B 15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2013.5
– volume: 170
  year: 2016
  ident: B9
  article-title: HLA and Delayed Drug-Induced Hypersensitivity
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000448217
– volume: 45
  year: 2001
  ident: B1
  article-title: Dapsone and Sulfones in Dermatology: Overview and Update
  publication-title: J Am Acad Dermatol
  doi: 10.1067/mjd.2001.114733
– volume: 62
  year: 2001
  ident: B43
  article-title: Analysis of the Frequencies of HLA-A, B, and C Alleles and Haplotypes in the Five Major Ethnic Groups of the United States Reveals High Levels of Diversity in These Loci and Contrasting Distribution Patterns in These Populations
  publication-title: Hum Immunol
  doi: 10.1016/s0198-8859(01)00298-1
– volume: 96
  year: 2017
  ident: B2
  article-title: A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients With an Emphasis on Preventing Adverse Drug Reactions With Genetic Testing
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.16-0628
– volume: 183
  year: 2011
  ident: B53
  article-title: Considerations When Prescribing Trimethoprim-Sulfamethoxazole
  publication-title: CMAJ
  doi: 10.1503/cmaj.111152
– volume: 155
  year: 2006
  ident: B14
  article-title: Variability in the Clinical Pattern of Cutaneous Side-Effects of Drugs With Systemic Symptoms: Does a DRESS Syndrome Really Exist
  publication-title: Br J Dermatol
  doi: 10.1111/j.1365-2133.2006.07284.x
SSID ssj0000493335
Score 2.4479978
Snippet HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several...
allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies....
HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 661135
SubjectTerms Adolescent
Adult
Aged
Alleles
Asian People - statistics & numerical data
Child
Child, Preschool
Cytochrome P-450 Enzyme System - genetics
cytochrome P450
Dapsone - adverse effects
dapsone-induced severe cutaneous adverse reactions
Female
Genetic Association Studies
Genetic Markers
Genotype
HLA class I and II alleles
HLA-B Antigens - classification
HLA-B Antigens - genetics
HLA-B13:01
Humans
Immunology
Male
Middle Aged
Molecular Docking Simulation
Polymorphism, Genetic
Prospective Studies
Skin - drug effects
Skin - pathology
Thais and Taiwaneses
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA5SEHwR63ValQg-CbGTSTKZ-NYrq6gUbaFvIZczdMRuy87ug__ek2S77oroi6-ZhAnnnCTnIyffR8hrHXsDXnWsC0EziTk981wDawKOkKAgZkmWT5_bybn8cKEu1qS-Uk1YoQcuhtuLvVO9F96bECR4aaQKuJ9GU0cfg4K0--KZtwamvpW8VwihyjUmojCz1w9XVwvEgw1_i0cSz_Juvw6izNf_pyTz91rJtcPn5AG5v8wa6X6Z7Ta5A9OH5G7RkfzxiAyTj_vsgAv6rub0_UgdPZ2lC5i0ldH0Ggdm9LqnRy6VfgBLch0BIv0KGMdADxeYIML1YqRZnXkE-gXKc4eRDlN6dukGelroV8fH5Pzk-OxwwpYaCizg6pozRCfO-CBaFxsZEHpK1-oehAmmi51P7GaIEV0rdN162UpXt9jMpepcIpt34gnZmuLUnhEaTI0ORSSug5LAMXfzuvdNML7p-r7zFalvDWrDkmA86Vx8twg0kg9s9oFNPrDFBxV5sxpyU9g1_tb5IHlp1TERY-cGDBe7DBf7r3CpyKtbH1tcSOl2pJjYNmivJmmv84o8LT5f_UogCtVC6IrojWjYmMvml-lwmcm6O55AGd_5H5PfJfeSPXK9pXxOtuazBbzAnGjuX-bw_wmrPgy-
  priority: 102
  providerName: Directory of Open Access Journals
Title HLA-B13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
URI https://www.ncbi.nlm.nih.gov/pubmed/34017337
https://www.proquest.com/docview/2531218791
https://pubmed.ncbi.nlm.nih.gov/PMC8130671
https://doaj.org/article/dfa5fb3bb9cc4eb4945c718d90dbdc5e
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKERIXxLvhURmJE5JLHDtxgoRQWygLoqiCrrS3yK_QoHa3TXYl-u-ZsbMrFq0QlxwcO3Zmxpn5Yns-Ql4q11Te5CUrrVVMQkzPDFeeZRZaSJ97FyhZjr8Wo7H8PMknW2RJbzUIsN8I7ZBPatyd7_26un4HE_4tIk7wt6-b9uJiAVAv43vgbbjIb5Cb4JgUMjkcD9H-zxgMCxEoN3lRSAamLOM65-anrHmqkNB_UxT692bKP7zT0V1yZwgr6X60g3tky0_vk1uRaPL6AWlHX_bZARf0Tcrpp55qetLhCg1-6yge1_EdnTX0vca9IZ4hn4f1jn73YOieHi4ggvSzRU8DfXPv6Tcfz0P0tJ3S0zPd0pOYn7V_SMZHH04PR2wgWWAWpt-cAXzRlbGi0C6TFrCp1IVqvKhsVbrSYPozAJG6ECotjCykTgso5jIvNWaj1-IR2Z7C0HYItVUKGgeormwuPYfgzqjGZLYyWdk0pUlIuhRobYcM5EiEcV4DEkEd1EEHNeqgjjpIyKtVk8uYfuNflQ9QS6uKmDk7FMy6H_UwEWvX6LwxwpjKWumNrGRuwT-7KnXG2dwn5MVSxzXMNFw-iSKuM5BXhuTsPCGPo85XXQmAqUoIlRC1Zg1rY1m_M23PQjbvkiNq40_-o9-n5Da-bthvKZ-R7Xm38M8hJpqb3fAvAa4fJ3w3WP1vUIULgQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA-B13+%3A01+Is+a+Predictive+Marker+of+Dapsone-Induced+Severe+Cutaneous+Adverse+Reactions+in+Thai+Patients&rft.jtitle=Frontiers+in+immunology&rft.au=Satapornpong%2C+Patompong&rft.au=Pratoomwun%2C+Jirawat&rft.au=Rerknimitr%2C+Pawinee&rft.au=Klaewsongkram%2C+Jettanong&rft.date=2021-05-04&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=12&rft.spage=661135&rft_id=info:doi/10.3389%2Ffimmu.2021.661135&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon